A 72-year-old woman with chronic obstructive pulmonary disease (COPD, FEV₁ 35% predicted) and severe osteoarthritis of the knees is admitted to hospital with acute exacerbation of COPD. Her baseline respiratory rate is 18/min, PaO₂ 65 mmHg, and PaCO₂ 48 mmHg on supplemental oxygen. She has been on morphine 10 mg every 6 hours for pain control at home. The admitting physician prescribes morphine 15 mg IV stat for acute pain, followed by 10 mg IV every 4 hours. Within 2 hours of the first dose, the patient's respiratory rate drops to 10/min, PaO₂ falls to 52 mmHg, and she becomes drowsy. What is the most appropriate immediate management?

Explanation

## Opioid-Induced Respiratory Depression: Emergency Management **Key Point:** Opioid-induced respiratory depression is a life-threatening emergency requiring immediate reversal with naloxone, a competitive opioid antagonist. Naloxone has rapid onset and can be titrated to restore spontaneous ventilation without complete analgesia loss. ### Clinical Context: Why This Patient Is at High Risk 1. **Underlying respiratory compromise**: COPD with baseline hypercapnia (PaCO₂ 48 mmHg) and hypoxemia (PaO₂ 65 mmHg) — opioids suppress the respiratory drive further. 2. **Dose escalation**: Morphine dose increased from 10 mg every 6 hours (home) to 15 mg IV stat + 10 mg every 4 hours (hospital) — excessive for acute exacerbation context. 3. **Acute illness**: COPD exacerbation increases sensitivity to opioid-induced respiratory depression. 4. **Signs of overdose**: RR 10/min (critical; normal ≥12), PaO₂ 52 mmHg (severe hypoxemia), drowsiness (CNS depression). ### Naloxone: Mechanism and Use **High-Yield:** Naloxone is a competitive opioid antagonist that rapidly reverses all opioid effects (analgesia, respiratory depression, sedation) by displacing opioids from μ-receptors. #### Dosing and Administration | Parameter | Detail | |-----------|--------| | **Initial dose** | 0.4–0.8 mg IV (push) | | **Repeat interval** | Every 2–3 minutes | | **Maximum dose** | 10 mg (rarely needed) | | **Onset** | 1–2 minutes IV; 2–3 minutes IM/SC | | **Duration** | 30–90 minutes (shorter than most opioids) | | **Route alternatives** | IM, SC, intranasal (if IV access unavailable) | **Clinical Pearl:** Naloxone duration is shorter than morphine — the patient may relapse into respiratory depression after naloxone wears off. Continuous monitoring and repeat doses or naloxone infusion (0.4 mg/hour) may be needed. ### Post-Naloxone Management 1. **Continuous monitoring**: Pulse oximetry, capnography, respiratory rate, level of consciousness. 2. **Mechanical ventilation readiness**: Have intubation equipment at bedside; this patient may need ventilatory support if respiratory depression recurs. 3. **Avoid re-dosing morphine**: Once respiratory depression is reversed, do NOT resume the same morphine regimen. Use lower doses (e.g., 5 mg IV every 6–8 hours) with careful titration. 4. **Reassess analgesia**: Balance pain control with respiratory safety; consider non-opioid analgesics (paracetamol, NSAIDs if not contraindicated) or regional anesthesia (e.g., epidural for knee pain). **Mnemonic:** **NALOXONE** = **N**eed **A**ctive **L**ifesaving **O**pioid **X**anthine **O**verdose **N**eutralization **E**mergency. ### Why Other Options Fail ```mermaid flowchart TD A[Opioid-induced respiratory depression]:::urgent --> B{Immediate action?}:::decision B -->|Reduce dose only| C[❌ Inadequate — patient still hypoxic]:::urgent B -->|Stop opioid entirely| D[❌ Inadequate — does not reverse active overdose]:::urgent B -->|Flumazenil| E[❌ Wrong drug — for benzodiazepines, not opioids]:::urgent B -->|Naloxone IV| F[✓ Correct — reverses opioid effect immediately]:::action F --> G[Monitor respiratory rate, PaO₂, consciousness]:::action G --> H[Prepare for mechanical ventilation if needed]:::action ``` **Warning:** Flumazenil is a benzodiazepine antagonist, NOT an opioid antagonist. It will not reverse morphine-induced respiratory depression and may cause seizures if the patient is benzodiazepine-dependent. ## Preventing Opioid-Induced Respiratory Depression in High-Risk Patients **High-Yield:** In patients with COPD, sleep apnea, or baseline hypercapnia: - Use lower initial opioid doses (e.g., 50% of standard dose). - Avoid long-acting formulations; use short-acting agents with careful titration. - Monitor respiratory rate, oxygen saturation, and CO₂ retention closely. - Consider non-opioid analgesics and regional anesthesia as alternatives.